En studie av Obinutuzumab [RO5072759 (GA101)] i kombinasjon med CHOP kjemoterapi hos pasienter med tidligere ubehandlet avansert diffust stort B-celle lymfom (GATHER)
En fase II, åpen, multisenterstudie av effekt, sikkerhet og biomarkører hos pasienter med tidligere ubehandlet avansert diffust stort B-cellet lymfom behandlet med GA101 (RO5072759) i kombinasjon med CHOP kjemoterapi
This open-label, multicenter study will evaluate the efficacy and safety of obinutuzumab [RO5072759 (GA101)] in combination with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) chemotherapy in patients with advanced diffuse large B-cell lymphoma. Patients will receive 8 cycles of obinutuzumab (1000 mg intravenously on Day 1 of each 21-day cycle, during Cycle 1 obinutuzumab will also be infused on Days 8 and 15) in combination with CHOP chemotherapy on Day 1 of cycles 1 to 6. A substudy will investigate the drug-drug interaction of obinutuzumab with CHOP chemotherapy agents. For the substudy, an additional cohort of approximately 15 patients are planned to be enrolled at a subset of investigational sites.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Faktiske)
Registrering
Fase
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forente stater, 35294-3300
- University of Alabama at Birmingham
-
-
California
-
Encinitas, California, Forente stater, 92024
- cCare
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80045
- University of Colorado Cancer Center Department of Hematology
-
Denver, Colorado, Forente stater, 80218
- Rocky Mountain Cancer Ctr - Denver (Williams)
-
-
Connecticut
-
Norwalk, Connecticut, Forente stater, 06856
- Norwalk Hospital
-
-
Florida
-
Fort Myers, Florida, Forente stater, 33901-8101
- Florida Cancer Specialists; Department of Oncology
-
St. Petersburg, Florida, Forente stater, 33719
- Florida Cancer Specialists; Saint Petersburg
-
-
Georgia
-
Marietta, Georgia, Forente stater, 30060
- Northwest Georgia Oncology Centers PC - Marietta
-
-
Idaho
-
Coeur d'Alene, Idaho, Forente stater, 83814
- Kootenai Medical Center
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60611
- Northwestern University; Robert H. Lurie Comp Can Ctr
-
Peoria, Illinois, Forente stater, 61615-7828
- Onc Hem Assoc of Central IL
-
-
Iowa
-
Ames, Iowa, Forente stater, 50010
- McFarland Clinic
-
-
Kentucky
-
Louisville, Kentucky, Forente stater, 40245
- Jewish Cancer Care
-
-
Massachusetts
-
Worcester, Massachusetts, Forente stater, 01655
- University of Massachusetts Medical School
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48109-0934
- University of Michigan
-
-
Montana
-
Missoula, Montana, Forente stater, 59802
- MT Cancer Inst Fndtn; MT Can Spec
-
-
Nevada
-
Las Vegas, Nevada, Forente stater, 89128
- Comprehensive Cancer Centers of Nevada
-
-
New Jersey
-
Basking Ridge, New Jersey, Forente stater, 07920
- MSKCC at Basking Ridge
-
Hackensack, New Jersey, Forente stater, 07601
- Hackensack University Medical Center
-
-
New Mexico
-
Farmington, New Mexico, Forente stater, 87401
- San Juan Oncology Associates
-
-
New York
-
Commack, New York, Forente stater, 11725
- Memorial Sloan-Kettering; Cancer Center
-
New York, New York, Forente stater, 10065
- Memorial Sloan Kettering Cancer Center
-
Rockville Centre, New York, Forente stater, 11570
- MSKCC at Mercy Med Ctr
-
Sleepy Hollow, New York, Forente stater, 10591
- MSKCC at Sleepy Hollow
-
-
North Carolina
-
High Point, North Carolina, Forente stater, 27262
- Emerywood Hematology and Onc
-
-
Oregon
-
Springfield, Oregon, Forente stater, 97477
- Willamette Valley Cancer Insitute and Research Center
-
-
South Carolina
-
Charleston, South Carolina, Forente stater, 29425
- Medical University of SC (MUSC)
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37203
- SCRI-Tennessee Oncology
-
-
Texas
-
Fort Worth, Texas, Forente stater, 76177
- Onc & Hem Assoc; USO Cent Pharm
-
Houston, Texas, Forente stater, 77030
- Methodist Hospital Research Institute
-
Houston, Texas, Forente stater, 77030
- MD Anderson Cancer Center Department of Lymphoma & Myeloma
-
San Antonio, Texas, Forente stater, 78229
- Cancer Therapy & Research Center
-
Tyler, Texas, Forente stater, 75702
- USO - Tyler Cancer Ctr
-
-
Virginia
-
Roanoke, Virginia, Forente stater, 24014
- Blue Ridge Cancer Care - Roanoke
-
-
Washington
-
Spokane, Washington, Forente stater, 99208
- Medical Oncology Associates
-
Vancouver, Washington, Forente stater, 98684
- Northwest Cancer Specialists - Vancouver
-
Yakima, Washington, Forente stater, 98902
- Yakima Valley Memorial Hospital/North Star Lodge
-
-
Wisconsin
-
Green Bay, Wisconsin, Forente stater, 54311
- Aurora Bay Care Medical Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Adult patients, ≥18 years of age
- Previously untreated cluster of differentiation antigen 20 (CD20)-positive diffuse large B-cell lymphoma
- Ann Arbour Stage III/IV and bulky II (mass >10 cm)
- At least one bi-dimensionally measurable lesion defined as >1.5 cm in its largest dimension by CT scan
- Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2
- Left ventricular ejection fraction ≥50%
- Adequate hematologic function
Exclusion Criteria:
- Transformed lymphoma (follicular IIIB) if previously treated with chemotherapy or immunotherapy
- Prior therapy for diffuse large B-cell lymphoma except for nodal biopsy or local irradiation
- Central nervous system (CNS) lymphoma, primary mediastinal large cell lymphoma, primary cutaneous lymphoma, primary effusion lymphoma
- Patients who received cytotoxic drugs or rituximab as part of their treatment for another condition (e.g. rheumatoid arthritis) or prior use of an anti-CD20 antibody
- Chemotherapy or other investigational therapy within 28 days prior to the start of Cycle 1
- Contraindication to any of the individual components of CHOP, including prior receipt of anthracyclines
- History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
- History of other malignancy, except for curatively treated basal or squamous cell carcinoma or melanoma of the skin or in situ carcinoma of the cervix, or malignancy treated with or without curative intent and in remission without treatment for ≥2 years prior to enrolment
- Positive for hepatitis B, hepatitis C, human immunodeficiency virus (HIV) or human T-cell leukemia virus (HTLV-1) infection
- Pregnant or lactating women
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: obinutuzumab + CHOP
Participants received 1000 mg obinutuzumab intravenously on Day 1 of each 21-day cycle for 8 cycles; during Cycle 1 administration also on Days 8 and 15. Participants also received standard CHOP therapy (cyclophosphamide, doxorubicin, vincristine and prednisone) for 6 cycles. |
1000 mg intravenously on Day 1 of each 21-day cycle, 8 cycles; during Cycle 1 administration also on Days 8 and 15. 750 mg/m^2 intravenous (IV), Day 1 of each 21-day cycle, 6 cycles. 50 mg/m^2 IV, Day 1 of each 21-cycle, 6 cycles. 100 mg/day, Days 1 through 5 of each 21-day cycle, 6 cycles. 1.4 mg/m^2 IV, Day 1 of each 21-day cycle, 6 cycles. |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Complete Response (CR) Rate as Assessed by the Investigator at the End of Treatment
Tidsramme: From the first dose of study treatment to end of treatment response assessment (approximately 228 to 258 days)
|
Complete response rate is defined as the percentage of participants with Complete Response (CR) according to the Revised Response Criteria for Malignant Lymphoma (Cheson et al., 2007). Disease response was evaluated by the investigator using regular clinical and laboratory examinations, fluorodeoxyglucose-positron emission tomography (FDG-PET) and computed tomography (CT). CR is the disappearance of all evidence of disease. |
From the first dose of study treatment to end of treatment response assessment (approximately 228 to 258 days)
|
|
Overall Response Rate (ORR) as Assessed by the Investigator at the End of Treatment
Tidsramme: From the first dose of study treatment to end of treatment response assessment (approximately 228 to 258 days)
|
Overall response rate was defined as the percentage of participants with Complete Response (CR) or Partial Response (PR) according to the Revised Response Criteria for Malignant Lymphoma (Cheson et al., 2007). Disease response was evaluated by the investigator using regular clinical and laboratory examinations, FDG-PET and computed tomography (CT). CR is the disappearance of all evidence of disease. PR is at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites. |
From the first dose of study treatment to end of treatment response assessment (approximately 228 to 258 days)
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Complete Response (CR) Rate as Assessed by the Independent Review Facility (IRF) at the End of Treatment
Tidsramme: From the first dose of study treatment to end of treatment response assessment (approximately 228 to 258 days)
|
Complete response rate is defined as the percentage of participants with Complete Response (CR) according to the Revised Response Criteria for Malignant Lymphoma (Cheson et al., 2007). Disease response was evaluated by the IRF using CT scans, PET scans and pertinent clinical information. CR is the disappearance of all evidence of disease. |
From the first dose of study treatment to end of treatment response assessment (approximately 228 to 258 days)
|
|
Overall Response Rate (ORR) as Assessed by the IRF at the End of Treatment
Tidsramme: From the first dose of study treatment to end of treatment response assessment (approximately 228 to 258 days)
|
Overall response rate was defined as the percentage of participants with Complete Response (CR) or Partial Response (PR) according to the Revised Response Criteria for Malignant Lymphoma (Cheson et al., 2007). Disease response was evaluated by the IRF using CT scans, PET scans and pertinent clinical information. CR is the disappearance of all evidence of disease. PR is at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites. |
From the first dose of study treatment to end of treatment response assessment (approximately 228 to 258 days)
|
|
Progression-Free Survival (PFS) as Assessed by the Investigator
Tidsramme: From the first dose of study treatment to PFS assessment (up to 64 months)
|
PFS was defined as the time from the date of the first dose of study treatment until the date of disease progression, relapse, or death from any cause. |
From the first dose of study treatment to PFS assessment (up to 64 months)
|
|
Duration of Response (DOR)
Tidsramme: From the response assessment to relapse, progression, or death (up to 64 months)
|
DOR is defined as first occurrence of documented response (CR or PR) until the first occurrence of relapse or progression or death of any cause. CR: disappearance of all evidence of disease. PR: at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites. |
From the response assessment to relapse, progression, or death (up to 64 months)
|
|
Percentage of Participants With Adverse Events as a Measure of Safety
Tidsramme: From the first dose of study treatment to end of study (up to 5 years 4 months)
|
An adverse event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug or other protocol-imposed intervention. Preexisting conditions that worsened during the study were reported as adverse events. |
From the first dose of study treatment to end of study (up to 5 years 4 months)
|
|
Number of Participants With Grade 3 to 4 Infusion-Related (IRR) Adverse Events (AE) in Participants Receiving Shorter Duration Infusion (SDI)
Tidsramme: From the first dose of study treatment to end of treatment response assessment (approximately 228 to 258 days)
|
SDI 120 is a shorter duration infusion of 120 minutes and SDI 90 is shorter duration infusion of 90 minutes. Grade 3 IRR AE: Prolonged (e.g., not rapidly responsive to symptomatic medication and/or brief interruption of infusion); recurrence of symptoms following initial improvement; hospitalization indicated for clinical sequelae. Grade 4 IRR AE: Life-threatening consequences; urgent intervention indicated. |
From the first dose of study treatment to end of treatment response assessment (approximately 228 to 258 days)
|
|
Pharmacokinetics (PK): Maximum Concentration Observed (Cmax) for Obinutuzumab
Tidsramme: Cycle 1 Day 1 pre and post dose, Days 3,5, Day 8 pre and post-dose, Day 15 pre-dose. Cycle 8 Day 1 pre and post-dose, Days 5,8,12
|
Blood was collected for PK Parameters. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA) measured in micrograms per milliliter (μg/mL). |
Cycle 1 Day 1 pre and post dose, Days 3,5, Day 8 pre and post-dose, Day 15 pre-dose. Cycle 8 Day 1 pre and post-dose, Days 5,8,12
|
|
Pharmacokinetics: Terminal Half-Life (t1/2) for Obinutuzumab
Tidsramme: Cycle 1 Day 1 pre and post dose, Days 3,5, Day 8 pre and post-dose, Day 15 pre-dose. Cycle 8 Day 1 pre and post-dose, Days 5,8,12
|
T1/2 is the time required for the concentration of the drug to reach half of its original value. Blood was collected for PK Parameters. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA) measured in days |
Cycle 1 Day 1 pre and post dose, Days 3,5, Day 8 pre and post-dose, Day 15 pre-dose. Cycle 8 Day 1 pre and post-dose, Days 5,8,12
|
|
Pharmacokinetics: Clearance (Cl) for Obinutuzumab
Tidsramme: Cycle 1 Day 1 pre and post dose, Days 3,5, Day 8 pre and post-dose, Day 15 pre-dose. Cycle 8 Day 1 pre and post-dose, Days 5,8,12
|
Cl is the volume of serum cleared of the drug per unit of time. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA) measured in milliliters/day (mL/day). |
Cycle 1 Day 1 pre and post dose, Days 3,5, Day 8 pre and post-dose, Day 15 pre-dose. Cycle 8 Day 1 pre and post-dose, Days 5,8,12
|
|
Pharmacokinetics: Volume of Distribution (V) for Obinutuzumab
Tidsramme: Cycle 1 Day 1 pre and post dose, Days 3,5, Day 8 pre and post-dose, Day 15 pre-dose. Cycle 8 Day 1 pre and post-dose, Days 5,8,12
|
V is the apparent volume in which a drug is distributed in the body. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA) measured in milliliters (mL). |
Cycle 1 Day 1 pre and post dose, Days 3,5, Day 8 pre and post-dose, Day 15 pre-dose. Cycle 8 Day 1 pre and post-dose, Days 5,8,12
|
|
Pharmacokinetics: Area Under the Concentration-Time Curve 7 Day (AUC7day)
Tidsramme: Cycle 1 Day 1 pre and post dose, Days 3,5, Day 8 pre and post-dose, Day 15 pre-dose. Cycle 8 Day 1 pre and post-dose, Days 5,8,12
|
Blood was collected for PK parameters. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA) measured in in day times micrograms per milliliter (day*μg/mL). |
Cycle 1 Day 1 pre and post dose, Days 3,5, Day 8 pre and post-dose, Day 15 pre-dose. Cycle 8 Day 1 pre and post-dose, Days 5,8,12
|
|
Pharmacodynamics: Number of Participants With Peripheral Blood B-cell Depletion
Tidsramme: From end of study treatment up to approximately 30 months
|
B-cell depletion was defined as a CD19 result < 0.07 × 10^9/L after at least one dose of study drug had been administered. Participants were evaluated during a 30-month post-treatment follow-up period following the completion of active study treatment (Cycle 8 [each cycle = 21 days]). Total study duration across active treatment and follow-up was up to approximately 5 years. |
From end of study treatment up to approximately 30 months
|
|
Pharmacodynamics: Number of Participants With Peripheral Blood B-cell Recovery
Tidsramme: Up to approximately 30 months
|
B-cell recovery was defined as a CD19 result >= 0.07 × 10^9/L, where CD19 was previously depleted. B-cell recovery was only considered possible following the last dose of study treatment. The number of participants with B-cell recovery from End of Treatment to 6 months of Follow-up is reported in two categories: Recovery with Progressive Disease (PD) [PD before B-cell recovery or PD within 45 days after recovery] or Recovery without PD. PD required one of the following: 50% increase in the absolute number of circulating lymphocytes, Appearance of new palpable lymph nodes, 50% increase in the longest diameter of any previous site of lymphadenopathy, 50% increase in the enlargement of the liver and/or spleen or Transformation to a more aggressive histology. |
Up to approximately 30 months
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Etterforskere
Etterforskere
- Studieleder: Clinical Trials, Genentech, Inc.
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Gibiansky E, Gibiansky L, Buchheit V, Frey N, Brewster M, Fingerle-Rowson G, Jamois C. Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study. Br J Clin Pharmacol. 2019 Sep;85(9):1935-1945. doi: 10.1111/bcp.13974. Epub 2019 Jul 12.
- Sharman JP, Forero-Torres A, Costa LJ, Flinn IW, Inhorn L, Kelly K, Bessudo A, Fayad LE, Kaminski MS, Evens AM, Flowers CR, Sahin D, Mundt KE, Sandmann T, Fingerle-Rowson G, Vignal C, Mobasher M, Zelenetz AD. Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study. Leuk Lymphoma. 2019 Apr;60(4):894-903. doi: 10.1080/10428194.2018.1515940. Epub 2018 Oct 2.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Faktiske)
Primær fullføring
Studiet fullført (Faktiske)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Antatt)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Neoplasmer
- Sykdommer i immunsystemet
- Neoplasmer etter histologisk type
- Lymfesykdommer
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Lymfom, Non-Hodgkin
- Lymfom
- Hemic og lymfatiske sykdommer
- Lymfom, B-celle
- Organiske kjemikalier
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ringen
- Hydrokarboner
- Hydrokarboner, syklisk
- Karbohydrater
- Alkaloider
- Polysykliske aromatiske hydrokarboner
- Hydrokarboner, aromatisk
- Polysykliske forbindelser
- Glykosider
- Indoler
- Gravadienes
- Gravaner
- Steroider
- Smeltede ringforbindelser
- Fosforamid -sennep
- Nitrogen sennepsforbindelser
- Sennepsforbindelser
- Hydrokarboner, halogenert
- Fosforamider
- Organofosforforbindelser
- Gravadienedioler
- Vinca -alkaloider
- Secologanin tryptaminalkaloider
- Indolalkaloider
- Indolizidiner
- Indolisiner
- Antracykliner
- Naphthacenes
- Aminoglykosider
- Daunorubicin
- Prednison
- Cyklofosfamid
- Doxorubicin
- Vincristine
- Obinutuzumab
Andre studie-ID-numre
Andre studie-ID-numre
- GAO4915g
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .